Market Pulse Archives

Dec. 5, 2016, 8:14 a.m. EST

Cerecor Inc. shares drop 37% after midstage trial failure

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Cerecor Inc. (CERC)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Emma Court

Cerecor Inc. /zigman2/quotes/201368871/composite CERC +3.04% shares dropped 37% in pre-market trade Monday after the company said its midstage clinical trial for a nicotine withdrawal treatment failed to meet its primary objective. The company is also developing the CERC-501 treatment for Major Depressive Disorder, which it said it will continue to do. The biotech, which was valued at $1.75 at Friday's close, saw shares sink 47.8% year-to-date, compared with a 7.2% rise in the S&P 500 /zigman2/quotes/210599714/realtime SPX +0.47% .

/zigman2/quotes/201368871/composite
US : U.S.: Nasdaq
$ 2.37
+0.07 +3.04%
Volume: 596,331
Oct. 20, 2020 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$172.27 million
Rev. per Employee
$286,356
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
3,443.12
+16.20 +0.47%
Volume: 2.10B
Oct. 20, 2020 4:20p
loading...

Get news alerts on Cerecor Inc. — or create your own.
This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.